Video

The Detection of Galectin-1 in Head and Neck Cancer

Dhanya K. Nambiar, PhD, Stanford University, discusses the detection of Galectin-1 for patients with head and neck cancer.

Dhanya K. Nambiar, PhD, Stanford University, discusses the detection of Galectin-1 for patients with head and neck cancer.

Galectin-1 can be detected in patient blood samples, Nambiar explains. Patients with head and neck cancer who are treated with radiation demonstrate higher levels of Galectin-1.

If one correlates the Galectin-1 level with the number of T cells in the blood, they are shown to decrease if the patient has received radiation.

Related Videos
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Laura A. Huppert, MD
Polly Niravath, MD